These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22410436)

  • 21. Risk factors and outcome of human immunodeficiency virus-infected patients with sporadic multidrug-resistant tuberculosis in New York City.
    Mannheimer SB; Sepkowitz KA; Stoeckle M; Friedman CR; Hafner A; Riley LW
    Int J Tuberc Lung Dis; 1997 Aug; 1(4):319-25. PubMed ID: 9432387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
    Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
    Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000-2009.
    van Altena R; de Vries G; Haar CH; de Lange WC; Magis-Escurra C; van den Hof S; van Soolingen D; Boeree MJ; van der Werf TS
    Int J Tuberc Lung Dis; 2015 Apr; 19(4):406-12. PubMed ID: 25859995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
    Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
    J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.
    Anger HA; Dworkin F; Sharma S; Munsiff SS; Nilsen DM; Ahuja SD
    J Antimicrob Chemother; 2010 Apr; 65(4):775-83. PubMed ID: 20150181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low rates of recurrence after successful treatment of multidrug-resistant tuberculosis in Tomsk, Russia.
    Gelmanova IY; Ahmad Khan F; Becerra MC; Zemlyanaya NA; Unakova IA; Andreev YG; Berezina VI; Pavlova VE; Shin S; Yedilbayev AB; Krasnov VA; Keshavjee S
    Int J Tuberc Lung Dis; 2015 Apr; 19(4):399-405. PubMed ID: 25859994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis.
    Kim DH; Kim HJ; Park SK; Kong SJ; Kim YS; Kim TH; Kim EK; Lee KM; Lee SS; Park JS; Koh WJ; Lee CH; Shim TS
    Am J Respir Crit Care Med; 2010 Jul; 182(1):113-9. PubMed ID: 20224066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Linezolid in the treatment of multidrug-resistant tuberculosis.
    Schecter GF; Scott C; True L; Raftery A; Flood J; Mase S
    Clin Infect Dis; 2010 Jan; 50(1):49-55. PubMed ID: 19947856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-resistant tuberculosis in Israel: risk factors and treatment outcomes.
    Mor Z; Goldblatt D; Kaidar-Shwartz H; Cedar N; Rorman E; Chemtob D
    Int J Tuberc Lung Dis; 2014 Oct; 18(10):1195-201. PubMed ID: 25216833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre.
    Shu CC; Lee CH; Lee MC; Wang JY; Yu CJ; Lee LN
    Int J Tuberc Lung Dis; 2013 Jul; 17(7):934-9. PubMed ID: 23743313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case-control study from China.
    Wang K; Chen S; Wang X; Zhong J; Wang X; Huai P; Wu L; Wang L; Jiang S; Li J; Peng Y; Yao H; Ma W
    Microb Drug Resist; 2014 Aug; 20(4):294-300. PubMed ID: 24328894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic.
    Rodriguez M; Monedero I; Caminero JA; Encarnación M; Dominguez Y; Acosta I; Muñoz E; Camilo E; Martinez-Selmo S; de los Santos S; del Granado M; Casals M; Cayla J; Marcelino B
    Int J Tuberc Lung Dis; 2013 Apr; 17(4):520-5. PubMed ID: 23485386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alanine transaminase and hemoglobin appear to predict the occurrence of antituberculosis medication hepatotoxicity; findings and implications in Botswana.
    Kesenogile B; Godman B; Rwegerera GM
    Expert Rev Anti Infect Ther; 2021 Mar; 19(3):379-391. PubMed ID: 32909487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linezolid in the treatment of MDR-TB: a retrospective clinical study.
    Xu HB; Jiang RH; Li L; Xiao HP
    Int J Tuberc Lung Dis; 2012; 16(3):358-63. PubMed ID: 22640450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era.
    Palacios E; Franke M; Muñoz M; Hurtado R; Dallman R; Chalco K; Guerra D; Mestanza L; Llaro K; Bonilla C; Sebastian J; Bayona J; Lygizos M; Anger H; Shin S
    Int J Tuberc Lung Dis; 2012; 16(3):348-54. PubMed ID: 22640448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
    Babalık A; Arda H; Bakırcı N; Ağca S; Oruç K; Kızıltaş S; Cetintaş G; Calışır HC
    Tuberk Toraks; 2012; 60(2):136-44. PubMed ID: 22779934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired Drug Resistance in Mycobacterium tuberculosis and Poor Outcomes among Patients with Multidrug-Resistant Tuberculosis.
    Kempker RR; Kipiani M; Mirtskhulava V; Tukvadze N; Magee MJ; Blumberg HM
    Emerg Infect Dis; 2015 Jun; 21(6):992-1001. PubMed ID: 25993036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prescription patterns and treatment outcomes of MDR-TB patients treated within and outside the National Tuberculosis Programme in Pham Ngoc Thach hospital, Viet Nam.
    Hoa NB; Khanh PH; Chinh NV; Hennig CM
    Trop Med Int Health; 2014 Sep; 19(9):1076-81. PubMed ID: 24995611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.